NCT04141592Recruiting
Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease
Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease: Cross-sectional Comparative Study Between Patients and Healthy Controls
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 153 (estimated)
- First submitted
- 23 Oct 2019
- Start date
- 5 Mar 2019
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Queen Mary University of London
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT04141592
What you commit to
- Study type: Observational
- Planned participants: 153
- From 5 Mar 2019 to the primary completion date, 31 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking medication associated with liver dysfunction (except methotrexate)
- Concomitant immunosuppressive medications (except methotrexate, short course oral steroids or inhaled corticosteroids)
- Any major organ transplant (excluding corneal or hair transplant)
Other illness
- Type 1 Diabetes Mellitus
- Other form of liver disease (other than NAFLD)
- o Viral hepatitis, Auto-immune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, haemochromatosis, Sarcoidosis, cystic fibrosis, sickle cell disease
- Auto-immune disease which in the investigator's opinion may confound immune profiling
Other
- Unwilling or unable to give informed consent
- Currently pregnant
- Regular alcohol intake greater than 14 units a week for female participants and 21 units a week for male participants
Who the study is looking for
- Age ≥18 years
- Confirmed non-alcoholic Fatty liver disease (diagnosed clinically, radiologically or histologically)
- If diabetic, Diagnosed with Type 2 Diabetes Mellitus
- OR
- Healthy Control: no diagnosis of any liver condition including NAFLD
- o NAFLD excluded by Fibroscan Controlled Attenuation Parameter (CAP) score of \<222 dB/m
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Homerton University Hospital Foundation Trust Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.